Transaxillary endoscopic breast augmentation evidence is best understood as a comparison between two different access philosophies. The transaxillary route reaches the breast pocket through an incision in the armpit, while an inframammary approach enters through the fold beneath the breast. Endoscopy does not change the location of the skin incision; it changes what the surgeon can see and control while creating the implant pocket from that remote entry point.
This review of transaxillary endoscopic breast augmentation evidence traces the route from the blind axillary operations described in the 1970s to modern video-assisted dissection. It focuses on primary cosmetic augmentation, not reconstruction, revision surgery or breast cancer procedures. The literature supports the transaxillary approach as a selective alternative for appropriately assessed patients, particularly when avoiding a scar on the breast mound is a high priority. It does not prove that endoscopic access is universally safer, less painful or more accurate than an inframammary incision.
What is the transaxillary approach?
In transaxillary breast augmentation, the incision is placed in a natural crease or a carefully chosen line within the axilla. A working tunnel is developed from the armpit toward the breast pocket. Depending on the plan, the implant may be placed in a submuscular, subfascial or selected dual-plane relationship. The breast itself is not cut, so the visible scar is away from the breast aesthetic unit.
That remote access creates both the attraction and the technical problem. The incision can be discreet in clothing and does not sit on the breast mound, but the surgeon must work along a longer path to reach the pocket. Without visual assistance, the early operation depended on blunt dissection and tactile judgement. The surgeon could not directly inspect the entire pocket while releasing the pectoralis muscle, controlling perforators or deciding whether the new inframammary fold was symmetrical.
It is important to separate access route from implant plane. “Transaxillary” describes where the surgeon enters. “Submuscular,” “subfascial” and “dual plane” describe the tissue relationship around the device. An endoscopic transaxillary operation can use different planes in selected patients, but the available evidence often combines incision, plane, implant surface, implant shape and surgeon experience. That makes simple claims about the route difficult to interpret.
From a blind technique to endoscopic visualization
The axillary route was described in the peer-reviewed literature in 1973 by H. Hoehler. The historical report proposed that the axilla could conceal the scar while providing an aesthetic result comparable to an inframammary exposure. Subsequent subpectoral series refined the route and identified a recurring limitation: a remote incision made it harder to see and accurately shape the pocket, especially at the lower and medial borders.
By the 1980s, surgeons were describing longer follow-up, the relationship between the pectoralis muscle and implant, and the situations in which the route was less suitable. Tebbetts’ 1984 series of 90 patients reported a 5.6% Baker III/IV capsular-contracture rate among the 63 patients with two to five years of follow-up and described the approach as an alternative to inframammary and periareolar access except in ptotic breasts or when extremely large prostheses were required. This was an important clinical series, but it was not a randomized comparison and it predates modern implant designs and current safety communication.
Endoscopic assistance was introduced to solve the visual-control problem. Ho reported an endoscopic-assisted transaxillary technique in 1993, and Price, Eaves, Nahai, Jones and Bostwick reported endoscopic transaxillary subpectoral augmentation in 1994. The aim was not to make the tunnel disappear. It was to place a camera and light at the operative field so that the surgeon could observe muscle release, pocket boundaries and bleeding rather than relying on a blind instrument path.
Early endoscopic procedures were not identical. Some combined blunt dissection with endoscopic inspection; later descriptions used electrocautery under direct endoscopic vision for more of the dissection. Sim’s 2014 review describes the modern refinement as sharp electrocautery dissection under direct endoscopic vision, with attention to the costal origin of the pectoralis major, the pocket dimensions and the inframammary crease. That article is a useful technical review, but its favourable conclusions should be read alongside the fact that it is not a randomized comparison with inframammary surgery.
What the endoscope changes in practice
Endoscopy offers a magnified, illuminated view of a space that is otherwise difficult to inspect from the axilla. The surgeon can identify the pectoralis muscle, fascia, medial and lateral pocket limits, vessels and the lower boundary of the intended pocket. Electrocautery can be used under vision to divide selected tissue and control bleeding. A retractor can maintain a working space while the camera and instruments are coordinated.
The potential benefit is control, not a guaranteed outcome. A visible field may make dissection more deliberate and help the surgeon compare the pocket with preoperative markings. It may also make it possible to lower or define the inframammary fold in selected anatomy, or to adjust the pocket after using a sizer. The surgeon still has to interpret a two-dimensional monitor, maintain orientation and work through a remote entry site. A magnified image can be distorted, and the camera can lose the spatial cues that are more immediate through a direct inframammary incision.
Bleeding illustrates the difference between the old and newer methods. Blind blunt dissection can tear small vessels or perforators without showing the source clearly. Endoscopic electrocautery may improve haemostasis by allowing the operator to see and address a bleeding point. It does not eliminate bleeding, and a significant or uncontrolled haemorrhage may require conversion to an open incision. In Kolker, Austen and Slavin’s 197-patient series, one patient (0.5%) required conversion for bleeding and three patients (1.5%) required conversion for inadequate implant position or breast shape.
Endoscopy can also support a more reproducible sequence of dissection. The surgeon may develop the axillary working space, address the medial pocket, release the relevant pectoral origin, and then refine the inferior and lateral limits. The exact sequence is technique-specific and should not be treated as a patient instruction manual. The evidence-based point is that visualization can reduce reliance on blind force, but it cannot replace anatomical knowledge, device handling or judgement about when the route is no longer appropriate.
Who may be a reasonable candidate?
Patient selection is central to the published experience. The route is most often discussed for primary augmentation in a patient with breast hypoplasia, a relatively stable breast envelope and a strong preference for keeping the breast mound free of an incision. Several authors have highlighted young patients with an indistinct or absent inframammary fold, because creating a new fold is part of the surgical plan rather than a matter of preserving a sharply defined existing one.
A patient may also value the route when scar visibility on the breast is a particular concern, including patients whose skin tends to develop conspicuous or hypertrophic scars. That preference is personal and should not be equated with a universal ethnic rule. Scar behaviour varies within every population, and an axillary scar is not necessarily invisible. It may widen, become darker or be noticeable when the arm is raised.
The route can be considered for selected implant shapes and fillers when the incision, implant dimensions, pocket and insertion method are compatible. Older literature focused heavily on saline implants because they could be inserted deflated through a smaller incision. Later series describe silicone-gel implants, including shaped and smooth round devices, using larger or carefully protected access incisions. The availability of an implant through an axillary route does not mean that every size, profile or shell is equally easy to place or equally suitable for every patient.
Good selection includes more than looking at breast volume. The consultation should assess the breast base, chest-wall shape, tissue thickness, nipple-to-fold distance, the position and definition of the existing fold, skin quality, asymmetry, pectoralis muscle size and activity, and the amount of lower-pole skin. A patient who wants a large device, a substantial fold change or correction of an established deformity may be better served by another access route or by a combined or staged plan.
Where the approach becomes limited
The most consistent limitation is that the axilla is remote from the breast mound. A direct inframammary incision gives a short, open view of the pocket and makes it easier to define the fold, control the lower border, inspect the implant and revise the pocket. Endoscopy narrows that difference but does not erase it.
Marked ptosis, pseudoptosis, a constricted lower pole and tuberous breast features require careful caution. An implant can add volume, but it does not remove excess skin or reliably elevate a low nipple. Lower-pole constriction may require scoring or reshaping that is easier to perform through a direct incision. Kolker and colleagues specifically identified deficient lower poles, a sharply defined fold with an areola-to-fold distance of 3.5 cm or less, pectoralis major hypertrophy, ptosis, pseudoptosis and tuberous deformity as features requiring judicious selection. In their series, the cases converted for inadequate position or shape included two tuberous breasts and one patient with ptosis.
Very large implants create another practical challenge. The incision has to accommodate safe delivery without damaging the shell, and the longer tunnel can make insertion and orientation more demanding. An implant that is technically insertable is not automatically a good match for the patient’s soft-tissue envelope. The route should not be selected to preserve a hidden scar at the expense of pocket control or tissue safety.
Revision surgery is a further limitation. If the patient later develops capsular contracture, malposition, rupture, significant ptosis or a need for tissue reshaping, an inframammary incision may offer better access even if the primary operation was transaxillary. Some secondary procedures can be approached endoscopically in experienced hands, but the original incision should not be marketed as a promise that all future implant problems can be treated through the armpit.
There are also equipment and training requirements. The operation uses a camera, light source, retractor and instruments, and the surgeon must learn to coordinate visual information with instruments entering from a different direction. The image is magnified and may be less intuitive than direct vision. Learning-curve claims from experienced single-surgeon series do not mean that all surgeons have the same training or that a short operation time is guaranteed.
What does the evidence show compared with an inframammary incision?
The fairest answer is mixed. The relevant studies are mainly retrospective cohorts, matched case-control studies and single-surgeon series. They can compare observed complications and patient experience, but they cannot fully separate the access route from patient age, anatomy, implant type, pocket, surgeon preference and the reason a patient chose a concealed scar.
Momeni and colleagues retrospectively compared 78 primary aesthetic patients who underwent either submuscular inframammary or endoscopically assisted transaxillary augmentation between 1997 and 2004. Both groups had low complication rates, and the authors reported higher satisfaction in the transaxillary group. Because the study was retrospective, small and based on a questionnaire rather than a blinded objective assessment, it shows that the hidden scar can matter to patients; it does not establish that the transaxillary route is clinically superior.
Lee, Kim and Kim later performed a matched case-control study of 364 primary, bilateral augmentations using shaped implants. One hundred and ninety-five patients had an inframammary approach and 169 had an endoscopic transaxillary approach. Implant type and size were matched, and the average follow-up was 27 months. Reported complication rates were 1.8% in the inframammary group and 2.7% in the transaxillary group, with no statistically significant difference in surgical complications (p = 0.593). This supports non-inferiority within that selected cohort, but the level-III design and shaped-implant population limit how broadly the result can be applied.
A newer seven-year retrospective cohort provides a useful counterweight to claims of less trauma. Chen and colleagues studied 194 primary bilateral augmentations performed with textured silicone-gel implants in a dual-plane pocket by the same team: 105 through an inframammary fold incision and 89 through an endoscopic transaxillary incision. The inframammary group had a shorter operation and lower visual-analogue pain scores during the first three postoperative days. Drainage volume, drainage duration and hospital stay did not differ significantly. The groups also differed in age and fertility status, with younger and more nulliparous patients more likely to choose transaxillary access, so the study cannot prove that incision alone caused the pain difference.
Large single-surgeon experience adds information about feasibility but not a direct comparator. Giordano and colleagues reported 306 consecutive endoscopic transaxillary augmentations from 1996 to 2005. Their series included subglandular, subfascioglandular and submusculofascial pockets; they reported three haematomas, five cases of capsular contracture, one postoperative infection and a 6.2% reoperation rate for implant malposition. The series shows that the procedure can be performed at scale, while the mixed planes, historical implants and lack of an inframammary control group limit comparative conclusions.
A 2024 case series reported outcomes in 1,389 endoscopic transaxillary augmentations performed by one surgeon from 2006 to 2021. All implants were smooth, round silicone-gel devices placed in subfascial or submuscular planes. The overall complication rate was 6.69%, with malposition at 3.64% and contracture at 1.74%. The authors described long-term experience and endoscopic management of many complications, but the study was level V evidence and had no direct inframammary comparison. It is therefore evidence of feasibility and one team’s outcomes, not a benchmark for every practice.
Taken together, the literature does not justify either extreme. Endoscopic transaxillary augmentation can achieve complication rates comparable to inframammary access in selected series, particularly when the surgeon is experienced and the patient’s anatomy is favourable. Inframammary access may offer shorter dissection, more direct control and less early pain in some cohorts. The visible-scar advantage of transaxillary surgery is real for many patients, but it is a patient-valued outcome rather than proof of better surgical control.
How should the comparison be interpreted?
“Comparable” needs a defined endpoint. It might mean similar rates of haematoma, infection, contracture or malposition. It might mean similar breast shape at follow-up, similar satisfaction or an acceptable scar. A study that finds no statistically significant difference in complications does not show that the two operations are identical in operative difficulty, pain, recovery or revision access.
It is also important not to treat a non-significant result as proof of equivalence. A study may be too small to detect a modest difference, may have unequal follow-up, or may combine complications that matter differently to patients. Conversely, a statistically significant pain difference in a retrospective cohort may reflect the longer path and dissection of the transaxillary operation, but it may also reflect group differences or perioperative protocol.
For the patient, the useful questions are specific: What incision and pocket are being proposed? How will the new fold be controlled? What implant dimensions can be introduced without excessive force? How does the plan address asymmetry, thin coverage, pectoralis activity or lower-pole limits? If a problem occurs, can it be treated through the original route, or would an inframammary incision likely be needed? A careful answer is more valuable than a universal claim that one scar location is best.
The broader planning literature also supports an anatomy-led discussion. Our evidence review on implant pocket placement explains why the relationship among breast tissue, fascia, muscle and implant changes the trade-offs. The review of dual-plane augmentation adds context about muscle coverage, lower-pole expansion and dynamic movement. These are related questions, not evidence that a transaxillary incision is automatically appropriate.
What this history means for modern decision-making
The evolution from a blind tunnel to endoscopic visualization is a story of improved information during surgery. It illustrates how technical equipment can address a genuine limitation: an incision away from the breast made it difficult to see the pocket and control the lower border. The modern procedure is more controlled than the original blind technique described in the 1970s, but modern control is not the same as universal suitability.
A patient who prioritises an unscarred breast mound and has favourable anatomy may reasonably discuss an endoscopic transaxillary option with a surgeon who performs it routinely. A patient with significant ptosis, a tight lower pole, marked asymmetry, a large implant request, a substantial fold change or a likely need for a lift may need a different approach. The decision is not made by the search term “scarless breast augmentation,” because the operation still creates a scar and may still require a future breast incision.
For plain-language procedural context, see the breast augmentation operation page. Questions about implant dimensions and why volume is not a cup-size promise are covered in the research review of implant dimensions, base width and cc. The practical breast augmentation safety and recovery guide can help readers distinguish general postoperative information from the evidence question addressed here. A package page may explain logistics, but it cannot determine whether an access route fits an individual anatomy.
Limitations of this review
This is a narrative evidence review, not a new systematic review, meta-analysis or individual surgical recommendation. The historical account relies on original PubMed records where available and later peer-reviewed reviews that describe the transition from blind to endoscopic access. The earliest reports often provide limited abstracts, different definitions and follow-up that would not meet current study standards.
The comparative evidence is particularly vulnerable to selection bias. Patients who choose a concealed axillary scar may differ from those who accept an inframammary scar in age, anatomy, cultural preferences and expectations. Surgeons may also select the approach according to fold definition, implant size, breast shape and previous surgery. The studies use different implant surfaces, shapes, pocket planes, pain protocols, complication definitions and follow-up periods. A single-surgeon series cannot establish results for every surgeon or hospital.
Finally, this article does not compare the route for reconstruction, transgender breast augmentation, revision surgery or correction of congenital breast differences. Those populations have different anatomy and goals. The evidence should be updated if newer prospective comparative trials, regulator information or standardized patient-reported outcome studies change the balance of knowledge.
Conclusion
Transaxillary endoscopic breast augmentation developed in response to a clear limitation of blind remote access: the surgeon could not reliably see the pocket, control bleeding or shape the inframammary fold. The introduction of endoscopy in the early 1990s added illumination, magnification and a way to perform more precise dissection under direct vision. Later series show that selected patients can achieve stable results without a scar on the breast mound.
Current transaxillary endoscopic breast augmentation evidence supports the route as a selective alternative, not a universal replacement for inframammary access. Matched and retrospective comparisons generally report similar complication outcomes in selected patients, while newer cohort data suggest that inframammary surgery may be shorter and less painful in some settings. The best choice depends on anatomy, implant dimensions, pocket, surgeon experience, scar priorities and the patient’s willingness to accept the limitations of remote access and possible future revision through another incision.
This article is educational and does not diagnose, select an implant or recommend a surgical route. A qualified plastic surgeon must examine the patient, discuss alternatives and explain how the proposed plan would be adapted if the anatomy or intraoperative findings do not support transaxillary access.
Frequently asked questions
What is transaxillary endoscopic breast augmentation?
It is breast augmentation performed through an incision in the armpit, using an endoscope to illuminate and magnify the implant pocket while the surgeon dissects and controls the space. The breast mound itself is not used for the access incision, but the axillary scar is still a real surgical scar.
When was endoscopic transaxillary breast augmentation developed?
The transaxillary route was reported in the 1970s, while endoscopic-assisted versions were reported in the early 1990s. Ho published an endoscopic-assisted transaxillary augmentation report in 1993, followed by a 1994 report of endoscopic transaxillary subpectoral augmentation by Price and colleagues.
Is transaxillary endoscopic augmentation safer than an inframammary incision?
Current comparative evidence does not establish universal superiority. Selected studies report similar complication rates, while a newer retrospective cohort found shorter operations and lower early pain with inframammary access. The results are influenced by patient selection, implant, pocket, surgeon experience and outcome definitions.
Who may not be a good candidate for the transaxillary route?
Marked ptosis, pseudoptosis, a constricted lower pole, tuberous features, pronounced asymmetry, pectoralis hypertrophy, a sharply defined fold with a short lower pole, a very large implant request or a likely need for revision may make the route less suitable. The decision requires examination rather than a checklist alone.
Can silicone implants be placed through the axilla?
Published modern series describe both saline and silicone-gel implants through an endoscopic transaxillary incision. Suitability depends on the implant’s size, dimensions, shell, insertion method, the access incision and the patient’s tissue envelope. Not every implant is equally practical through every route.
Will I need an inframammary incision if revision is required?
Possibly. Some problems can be managed through an axillary route by an experienced surgeon, but an inframammary incision may provide better direct access for contracture, malposition, rupture, significant ptosis or substantial pocket reshaping. A primary hidden scar does not guarantee scar-free revision.
Does an endoscope guarantee a natural-looking result?
No. Visualization can improve control of the pocket, but the result also depends on breast anatomy, implant dimensions, tissue coverage, muscle activity, healing and the surgeon’s experience. No incision route guarantees a particular shape, cup size, recovery time or absence of complications.
Does the transaxillary route leave no scar?
No. It avoids a scar on the breast mound by placing the incision in the axilla. The axillary scar may be discreet, but it can still be visible, widen, darken or become raised. Scar behaviour varies between patients and cannot be promised from the incision location alone.
Related reading and internal-link proposals
This article should link naturally to the implant pocket placement evidence review, the dual-plane augmentation review, the implant dimensions and base-width review, the current operation page and the practical breast augmentation safety guide. A single contextual link may point to the all-inclusive breast augmentation package page for logistical next steps; that page should not be used as evidence for technique superiority.
Sources and references
The visible source list for this article is stored with its academic record and includes the original historical reports, technical reviews and comparative studies described below. Source quality and population differences should be considered when interpreting every result.